Publications 2026

Hermansen JU, Yin Y, Tjønnfjord GE, Mato AR, Skånland SS (2026)
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia
Br J Haematol (in press)
DOI 10.1111/bjh.70603, PubMed 42267774

Publications 2025

Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Cell Death Dis, 16 (1), 555
DOI 10.1038/s41419-025-07884-7, PubMed 40701968

Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Clin Cancer Res, 31 (10), 1943-1955
DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050

Publications 2024

Hermansen JU, Yin Y, Rein ID, Skånland SS (2024)
Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery
NPJ Precis Oncol, 8 (1), 107
DOI 10.1038/s41698-024-00604-y, PubMed 38769096

Publications 2023

Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS (2023)
Standardized assays to monitor drug sensitivity in hematologic cancers
Cell Death Discov, 9 (1), 435
DOI 10.1038/s41420-023-01722-5, PubMed 38040674

Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, Tveita AA, Taskén K, Munthe LA, Tjønnfjord GE, Skånland SS (2023)
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Cell Death Discov, 9 (1), 125
DOI 10.1038/s41420-023-01426-w, PubMed 37055391

Publications 2022

Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS (2022)
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Clin Cancer Res, 28 (20), 4444-4455
DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013

Publications 2021

Yin YP, Ma LY, Cao GZ, Hua JH, Lv XT, Lin WC (2021)
FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11
Acta Pharmacol Sin, 43 (8), 2119-2127
DOI 10.1038/s41401-021-00817-y, PubMed 34893686

Publications 2020

Yin YP, Shi WH, Deng K, Liu XL, Li H, Lv XT, Lui VWY, Ding C, Hong B, Lin WC (2020)
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer
Acta Pharmacol Sin, 42 (8), 1298-1310
DOI 10.1038/s41401-020-00544-w, PubMed 33139838

Publications 2019

Liu X, Wang W, Yin Y, Li M, Li H, Xiang H, Xu A, Mei X, Hong B, Lin W (2019)
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer
Invest New Drugs, 37 (6), 1166-1176
DOI 10.1007/s10637-019-00750-2, PubMed 30825105

Publications 2016

Yin Y, Yang Y, Xiang X, Wang Q, Yang ZN, Blevins J, Lou Y, Yang XF (2016)
Insight into the Dual Functions of Bacterial Enhancer-Binding Protein Rrp2 of Borrelia burgdorferi
J Bacteriol, 198 (10), 1543-52
DOI 10.1128/JB.01010-15, PubMed 26977110